2012
DOI: 10.1093/annonc/mds400
|View full text |Cite
|
Sign up to set email alerts
|

Survival Analysis of a Randomized Phase III Trial Comparing Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Hormone-Sensitive Metastatic Prostate Cancer (GETUG-AFU 15/0403)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…They induce apoptosis by disrupting mitosis through nonfunctional microtubule formation . Co‐administration of docetaxel with prednisone remains the treatment standard for HRPC and has demonstrated efficacy in clinical trials . Due to its improved adverse effect profile compared to its analog cisplatin, the clinical use of carboplatin in advanced prostate cancer patients as a chemotherapeutic agent has also been explored .…”
Section: Introductionmentioning
confidence: 99%
“…They induce apoptosis by disrupting mitosis through nonfunctional microtubule formation . Co‐administration of docetaxel with prednisone remains the treatment standard for HRPC and has demonstrated efficacy in clinical trials . Due to its improved adverse effect profile compared to its analog cisplatin, the clinical use of carboplatin in advanced prostate cancer patients as a chemotherapeutic agent has also been explored .…”
Section: Introductionmentioning
confidence: 99%